Zacks Research Brokers Boost Earnings Estimates for AGIO

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Stock analysts at Zacks Research boosted their Q2 2026 earnings per share (EPS) estimates for shares of Agios Pharmaceuticals in a note issued to investors on Tuesday, May 19th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings per share of ($1.87) for the quarter, up from their prior estimate of ($1.90). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.19) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q3 2026 earnings at ($1.85) EPS, FY2026 earnings at ($7.24) EPS, Q1 2027 earnings at ($1.60) EPS, Q2 2027 earnings at ($1.61) EPS, Q3 2027 earnings at ($1.52) EPS, Q4 2027 earnings at ($1.43) EPS, FY2027 earnings at ($6.16) EPS, Q1 2028 earnings at ($1.19) EPS and FY2028 earnings at ($3.91) EPS.

Several other brokerages have also issued reports on AGIO. Wall Street Zen raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, March 22nd. Citigroup lifted their price objective on shares of Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Bank of America dropped their target price on shares of Agios Pharmaceuticals from $44.00 to $41.00 and set a “buy” rating on the stock in a research report on Tuesday, April 21st. Truist Financial cut their target price on shares of Agios Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, April 30th. Finally, HC Wainwright reduced their price target on shares of Agios Pharmaceuticals from $65.00 to $50.00 and set a “buy” rating for the company in a report on Monday, April 20th. Six investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $41.56.

Agios Pharmaceuticals Price Performance

NASDAQ AGIO opened at $28.50 on Thursday. The stock has a market capitalization of $1.69 billion, a P/E ratio of -3.93 and a beta of 0.58. The business has a 50 day simple moving average of $29.60 and a 200 day simple moving average of $29.67. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.81) by $0.12. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The company had revenue of $20.75 million for the quarter, compared to the consensus estimate of $13.30 million. The firm’s quarterly revenue was up 137.7% compared to the same quarter last year.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 3,141 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $109,024.11. Following the completion of the sale, the chief financial officer owned 54,998 shares of the company’s stock, valued at approximately $1,908,980.58. This trade represents a 5.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Krishnan Viswanadhan sold 2,959 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $27.80, for a total value of $82,260.20. Following the completion of the sale, the insider directly owned 5,141 shares of the company’s stock, valued at $142,919.80. This trade represents a 36.53% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 15,582 shares of company stock valued at $520,405. 5.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Agios Pharmaceuticals

Several hedge funds have recently bought and sold shares of AGIO. Bellevue Group AG increased its stake in Agios Pharmaceuticals by 3.5% during the 3rd quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock valued at $149,110,000 after purchasing an additional 124,586 shares in the last quarter. State Street Corp lifted its stake in shares of Agios Pharmaceuticals by 37.4% in the fourth quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock valued at $84,604,000 after buying an additional 845,433 shares in the last quarter. Erste Asset Management GmbH grew its holdings in shares of Agios Pharmaceuticals by 1.4% during the fourth quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company’s stock valued at $76,343,000 after buying an additional 40,000 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Agios Pharmaceuticals by 485.5% during the third quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after buying an additional 2,049,287 shares during the last quarter. Finally, Commodore Capital LP increased its position in shares of Agios Pharmaceuticals by 0.6% during the third quarter. Commodore Capital LP now owns 2,338,287 shares of the biopharmaceutical company’s stock worth $93,859,000 after acquiring an additional 13,287 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.